BR112021012019A2 - Domínio transmembranar derivado de proteína lrrc24 humana, uso terapêutico do mesmo, carga recombinante, construto de gene, vetor de expressão e método para distribuir uma carga a uma célula - Google Patents
Domínio transmembranar derivado de proteína lrrc24 humana, uso terapêutico do mesmo, carga recombinante, construto de gene, vetor de expressão e método para distribuir uma carga a uma célulaInfo
- Publication number
- BR112021012019A2 BR112021012019A2 BR112021012019A BR112021012019A BR112021012019A2 BR 112021012019 A2 BR112021012019 A2 BR 112021012019A2 BR 112021012019 A BR112021012019 A BR 112021012019A BR 112021012019 A BR112021012019 A BR 112021012019A BR 112021012019 A2 BR112021012019 A2 BR 112021012019A2
- Authority
- BR
- Brazil
- Prior art keywords
- transmembrane domain
- cargo
- protein
- human
- cell
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 8
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 239000013604 expression vector Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000000463 material Substances 0.000 abstract 3
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 abstract 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000003834 intracellular effect Effects 0.000 abstract 2
- 102000003839 Human Proteins Human genes 0.000 abstract 1
- 108090000144 Human Proteins Proteins 0.000 abstract 1
- 238000002716 delivery method Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Abstract
domínio transmembranar derivado de proteína lrrc24 humana, uso terapêutico do mesmo, carga recombinante, construto de gene, vetor de expressão e método para distribuir uma carga a uma célula. a presente invenção refere-se a um domínio transmembrana derivado da proteína lrrc24 humana. mais especificamente, a presente invenção refere-se a um domínio transmembrana derivado da proteína lrrc24 humana (domínio transmembrana lrrc24p) ou um peptídeo de penetração celular, e um sistema de entrega intracelular compreendendo o mesmo. o domínio transmembrana derivado da proteína lrrc24 humana da presente invenção pode ser usado para entregar materiais de carga, tais como compostos, biomoléculas e vários materiais poliméricos a células. uma vez que o domínio transmembrana lrrc24p da presente invenção exibe maior eficiência de penetração celular em comparação com os peptídeos de penetração celular convencionais e é derivado de proteínas humanas, evitando assim efeitos colaterais e respostas imunes causadas por peptídeos derivados de proteínas estranhas, ele pode ser utilmente usado como um método de entrega intracelular eficaz para compostos, biomoléculas e vários materiais poliméricos aplicados ao corpo humano.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180165438 | 2018-12-19 | ||
| KR1020190144779A KR102351041B1 (ko) | 2018-12-19 | 2019-11-13 | 인간 lrrc24 단백질 유래 세포막 투과 도메인 |
| PCT/KR2019/017829 WO2020130547A1 (ko) | 2018-12-19 | 2019-12-16 | 인간 엘알알씨24 단백질 유래 세포막 투과 도메인 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021012019A2 true BR112021012019A2 (pt) | 2021-11-03 |
Family
ID=71401249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021012019A BR112021012019A2 (pt) | 2018-12-19 | 2019-12-16 | Domínio transmembranar derivado de proteína lrrc24 humana, uso terapêutico do mesmo, carga recombinante, construto de gene, vetor de expressão e método para distribuir uma carga a uma célula |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220306718A1 (pt) |
| EP (1) | EP3875113A4 (pt) |
| JP (1) | JP7193633B2 (pt) |
| KR (1) | KR102351041B1 (pt) |
| CN (1) | CN113166216A (pt) |
| AU (1) | AU2019403533A1 (pt) |
| BR (1) | BR112021012019A2 (pt) |
| CA (1) | CA3122428A1 (pt) |
| PH (1) | PH12021551150A1 (pt) |
| SG (1) | SG11202105169WA (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102484312B1 (ko) * | 2020-05-14 | 2023-01-02 | 한국화학연구원 | 고효능 사스 코로나바이러스 2 항원 및 이를 포함하는 백신 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004020595A2 (en) * | 2002-08-29 | 2004-03-11 | Five Prime Therapeutics, Inc. | Novel human polypeptides encoded by polynucleotides |
| US20110033389A1 (en) * | 2009-04-29 | 2011-02-10 | Zhifeng Chen | Modified antibodies for passive immunotherapy |
| US10723806B2 (en) * | 2012-02-27 | 2020-07-28 | Riken | Method of introducing nucleic acid into plant cells |
| US10967000B2 (en) * | 2012-07-11 | 2021-04-06 | Gemvax & Kael Co., Ltd. | Cell-penetrating peptide, conjugate comprising same and composition comprising same |
| KR102166542B1 (ko) * | 2012-09-28 | 2020-10-16 | 주식회사 젬백스앤카엘 | 줄기세포 검출을 위한 텔로머라제 유래 펩티드 및 조영물질의 컨쥬게이트 및 이를 포함하는 조영제 |
| ES2722924T3 (es) * | 2012-12-05 | 2019-08-20 | Univ Heidelberg Ruprecht Karls | Conjugados de proteínas y péptidos multivalentes de penetración celular y sus usos |
| US20150329640A1 (en) * | 2012-12-20 | 2015-11-19 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| US20180133327A1 (en) * | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| CN107636017B (zh) * | 2015-04-10 | 2022-05-31 | 费尔丹生物公司 | 用于改进多肽负荷向靶真核细胞的细胞质转导的效率的基于多肽的穿梭剂，其用途、及与其相关的方法和试剂盒 |
| CN105112383B (zh) * | 2015-08-25 | 2018-12-14 | 三峡大学 | 细胞膜穿透肽hPP5及其用途 |
| CN105175526B (zh) * | 2015-08-25 | 2018-08-14 | 三峡大学 | 细胞膜穿透肽hPP8及其用途 |
| JP7250519B2 (ja) * | 2016-03-23 | 2023-04-03 | ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
| KR101848147B1 (ko) * | 2016-07-14 | 2018-04-11 | 건양대학교산학협력단 | 세포 투과성 hoxa9 융합단백질 및 이를 포함하는 폐암의 예방 또는 치료용 조성물 |
| IL249610A (en) * | 2016-12-15 | 2017-12-31 | Nat Inst Biotechnology Negev Ltd | Chimeric proteins for cancer treatment |
-
2019
- 2019-11-13 KR KR1020190144779A patent/KR102351041B1/ko active IP Right Grant
- 2019-12-16 EP EP19898351.2A patent/EP3875113A4/en active Pending
- 2019-12-16 CN CN201980079173.8A patent/CN113166216A/zh active Pending
- 2019-12-16 JP JP2021531077A patent/JP7193633B2/ja active Active
- 2019-12-16 AU AU2019403533A patent/AU2019403533A1/en active Pending
- 2019-12-16 SG SG11202105169WA patent/SG11202105169WA/en unknown
- 2019-12-16 US US17/296,622 patent/US20220306718A1/en active Pending
- 2019-12-16 CA CA3122428A patent/CA3122428A1/en active Pending
- 2019-12-16 BR BR112021012019A patent/BR112021012019A2/pt not_active IP Right Cessation
-
2021
- 2021-05-20 PH PH12021551150A patent/PH12021551150A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113166216A (zh) | 2021-07-23 |
| EP3875113A4 (en) | 2022-08-31 |
| JP2022510309A (ja) | 2022-01-26 |
| KR20200076582A (ko) | 2020-06-29 |
| AU2019403533A1 (en) | 2021-06-24 |
| JP7193633B2 (ja) | 2022-12-20 |
| CA3122428A1 (en) | 2020-06-25 |
| KR102351041B1 (ko) | 2022-01-13 |
| SG11202105169WA (en) | 2021-06-29 |
| EP3875113A1 (en) | 2021-09-08 |
| US20220306718A1 (en) | 2022-09-29 |
| PH12021551150A1 (en) | 2021-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019011277A2 (pt) | polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos. | |
| SA518390881B1 (ar) | Sirp-alpha أجزاء منشأة تتضمن نطاق أو صورة متغيرة منها | |
| BR112016015512A2 (pt) | proteínas quiméricas de fator viii e suas utilizações | |
| PE20190911A1 (es) | Composiciones y anticuerpos anti-lag-3 | |
| CR20180027A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer. | |
| BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| PE20190743A1 (es) | Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib | |
| CL2011000086A1 (es) | Anticuerpo aislado o proteina funcional contra el polipeptido baffr que inhibe la proliferacion de celulas b; secuencia nucleotidicas de dicho anticuerpo; vector y celula huesped que comprende dicha secuencia; y su uso para tratar enfermedades autoinmunes o neoplasias de celulas b. | |
| CL2020002012A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032) | |
| EA201892493A1 (ru) | Жидкая композиция нейротоксина, стабилизированная триптофаном или тирозином | |
| EA201491277A1 (ru) | Противораковый слитый белок | |
| MX2020000018A (es) | Potencializacion de componentes sanguineos de actividad anti-bacteriana de proteina litica y metodos y usos de estos. | |
| EA201990856A1 (ru) | Новые противомикробные агенты против бактерий enterococcus | |
| UY38069A (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
| BR112021012019A2 (pt) | Domínio transmembranar derivado de proteína lrrc24 humana, uso terapêutico do mesmo, carga recombinante, construto de gene, vetor de expressão e método para distribuir uma carga a uma célula | |
| PE20240123A1 (es) | Mutante de il-2 y aplicacion de este | |
| ES2828086T3 (es) | Confórmeros abiertos de HLA-B57 | |
| MA32770B1 (fr) | Anticorps anti-peptides igf-1/e humain modifie | |
| BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 | |
| BR112013025975A2 (pt) | proteína de fusão anticancerígena | |
| BR112019005001A2 (pt) | proteína de ligação ao antígeno, proteína de fusão, ácido nucleico, vetor recombinante, célula hospedeira recombinante, composição farmacêutica, uso médico da proteína de ligação ao antígeno e método de inibição do crescimento tumoral | |
| BR112019007343A2 (pt) | sequência de nucleotídeos expressando uma proteína de ancoragem de exossomo para uso como vacina | |
| EA202090802A1 (ru) | Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью | |
| BR112019024796A2 (pt) | Peptídeos e usos dos mesmos como agentes antivirais | |
| BR112022013978A2 (pt) | Peptídeo isolado, e, composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2753 DE 10-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |